Portfolio company
Tellus Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops biopharmaceutical treatments for white matter brain injury in premature infants to improve neurodevelopmental outcomes.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Pheno Therapeutics
This biotech company develops neuroprotective and remyelinating therapies for patients with multiple sclerosis and other neurodegenerative disorders.
Mahzi Therapeutics
This biotechnology company develops gene and antisense oligonucleotide therapies for patients with rare genetic neurodevelopmental disorders.
BE Therapeutics
This company develops engineered brain and spinal cord tissues to repair central nervous system damage for patients with neurodegeneration, stroke or trauma.
Oak Hill Bio
The company develops rare disease therapies and neonatal medicines for patients with neurodevelopmental disorders, autoimmune diseases and complications of premature birth.
Prophylix Pharma AS
The company develops antibody-based prophylactic treatments for fetal and neonatal alloimmune thrombocytopenia to prevent life-threatening bleeding and brain injury in newborns.
Convelo Therapeutics
This biotechnology company develops medicines to regenerate nerve cell myelin for patients with neurological disorders, including multiple sclerosis and paediatric leukodystrophies.
IAMA Therapeutics
This company develops small molecule drugs to treat neurodevelopmental and central nervous system disorders for patients with autism and epilepsy.
Tetra Therapeutics
This biotechnology company develops therapeutic drugs for patients suffering from neurological conditions such as Alzheimer's disease and Fragile X syndrome.